Nanoparticle-mediated drug delivery system for cardiovascular disease

International Heart Journal

Volumn 55, Issue 4, 2014, Pages 281-286

  Matoba, Tetsuya ^a   Egashira, Kensuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Inflammation; Ischemia reperfusion; Myocardial infarction; Nanotechnology

Indexed keywords

CD31 ANTIGEN; CLODRONIC ACID; CYCLOSPORIN; DOXORUBICIN; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROGOL; MATRIX METALLOPROTEINASE; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; N1177; NANOPARTICLE; PITAVASTATIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BEHAVIOR; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE TARGETING; HUMAN; MONONUCLEAR PHAGOCYTE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL NOISE RATIO;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; NANOPARTICLES;

EID: 84904109487     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-150     Document Type: Review

References (54)

1. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19: 311-30. (Review)
2. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013; 65: 1866-79.
3. Mulder WJ, Strijkers GJ, van Tilborg GA, Cormode DP, Fayad ZA, Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res 2009; 42: 904-14.
4. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. ISRN Pharm 2012; 2012: 738432.
5. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011; 63: 170-83. (Review)
6. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012; 161: 505-22. (Review)
7. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009; 100: 572-9. (Review)
8. Morgan MT, Carnahan MA, Finkelstein S, et al. Dendritic supramolecular assemblies for drug delivery. Chem Commun(Camb) 2005: 4309-11.
9. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. J Pharm Bioallied Sci 2010; 2: 282-9.
10. Gaucher G, Dufresne M-H, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88. (Review)
11. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa T. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm 1998; 45: 41-8.
12. Kimura S, Egashira K, Chen L, et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009; 53: 877-83.
13. Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/ rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 2014; 129: 896-906.
14. Tsukie N, Nakano K, Matoba T, et al. Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J Atheroscler Thromb 2013; 20: 32-45.
15. Nagahama R, Matoba T, Nakano K, Kim-Mitsuyama S, Sunagawa K, Egashira K. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 2012; 32: 2427-34.
16. Masuda S, Nakano K, Funakoshi K, et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J Atheroscler Thromb 2011; 18: 1043-53.
17. Chen L, Nakano K, Kimura S, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 2011; 57: 343-50.
18. Oda S, Nagahama R, Nakano K, et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg 2010; 52: 412-20.
19. Nakano K, Egashira K, Masuda S, et al. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv 2009; 2: 277-83.
20. Matoba T, Egashira K. Anti-inflammatory gene therapy for cardiovascular disease. Curr Gene Ther 2011; 11: 442-6. (Review)
21. Arsawang U, Saengsawang O, Rungrotmongkol T, et al. How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system? J Mol Graph Model 2011; 29: 591-6.
22. Mulder WJ, Fayad ZA. Nanomedicine captures cardiovascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 801-2.
23. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ Res 2011; 108: 593-606 (Review)
24. Baxter GF. The neutrophil as a mediator of myocardial ischemiareperfusion injury: time to move on. Basic Res Cardiol 2002; 97: 268-75. (Review)
25. Dauber IM, VanBenthuysen KM, Mcmurtry IF, et al. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res 1990; 66: 986-98.
26. Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 2009; 53: 709-17.
27. Asai T. Nanoparticle-mediated delivery of anticancer agents to tumor angiogenic vessels. Biol Pharm Bull 2012; 35: 1855-61. (Review)
28. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008; 83: 64-70.
29. Gibaud S, Demoy M, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci 1996; 85: 944-50.
30. Lee PY, Wang JX, Parisini E, Dascher CC, Nigrovic PA. Ly6 family proteins in neutrophil biology. J Leukoc Biol 2013; 94: 585-94. (Review)
31. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011; 29: 1005-10.
32. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994; 15: 215-20. (Review)
33. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000; 41: 147-62. (Review)
34. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-60. (Review)
35. Howard MD, Greineder CF, Hood ED, Muzykantov VR. Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release 2014; 177: 34-41.
36. Michalska M, Machtoub L, Manthey HD, et al. Visualization of vascular inflammation in the atherosclerotic mouse by ultrasmall superparamagnetic iron oxide vascular cell adhesion molecule-1-specific nanoparticles. Arterioscler Thromb Vasc Biol 2012; 32: 2350-7.
37. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the american heart association. Circulation 2014; 129: e28-292.
38. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012; 366: 54-63.
39. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75. (Review)
40. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30: 1282-92. (Review)
41. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009; 54: 49-57.
42. Hyafil F, Cornily J-C, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007; 13: 636-41.
43. Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat Mater 2014; 13: 125-38. (Review)
44. Morishige K, Kacher DF, Libby P, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010; 122: 1707-15.
45. Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19: 557-66 (Review)
46. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-20.
47. Holmes DR, Lerman A, Moreno PR, King SB 3rd, Sharma SK. Diagnosis and management of STEMI arising from plaque erosion. JACC Cardiovasc Imaging 2013; 6: 290-6.
48. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35. (Review)
49. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013; 123: 92-100. (Review)
50. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-8.
51. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
52. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-47.
53. Kimura S, Egashira K, Nakano K, et al. Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 2008; 118: S65-70.
54. Kubo M, Egashira K, Inoue T, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol 2009; 29: 796-801.